解放军医学院学报2017，Vol.38Issue(4)：381-384,4.DOI:10.3969/j.issn.2095-5227.2017.04.025
晚期肝癌患者对索拉非尼耐药机制的研究进展
Mechanism of sorafenib resistance in hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma (HCC) is one of the most common and aggressive malignant tumors in the world. As an orally-available kinase inhibitor, sorafenib is the exclusively standard clinical treatment against advanced hepatocellular carcinoma. However, the increasing level of resistance to sorafenib has seriously affected the therapeutic effect. Herein, we review the potential mechanism of sorafenib resistance in hepatocellular carcinoma from the aspects of microenvironment, hypoxia, epithelial mesenchymal, cancer stem cells and so on.关键词
晚期原发性肝细胞癌/索拉非尼/耐药Key words
advanced hepatocellular carcinoma/sorafenib/drug resistance分类
医药卫生引用本文复制引用
李晨曦,石燕,郭晓川,戴广海..晚期肝癌患者对索拉非尼耐药机制的研究进展[J].解放军医学院学报,2017,38(4):381-384,4.基金项目
国家自然科学基金面上项目(81372286) Supported by The National Natural Science Foundation of China (81372286) （81372286）
